Autopsy report · NCT03537599

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

“Poor acccrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 8 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 3 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Sumithira Vasu

Sponsor type

University, hospital or other

Conditions

Minimal Residual Disease; Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia

Interventions

Daratumumab; Donor Lymphocyte Infusion; Laboratory Biomarker Analysis

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
  “poor accrual” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.